Våra terapiområden

    • {%itemName%}
        {%brandMenuItems%}
    • {%itemName%} {%arrowSpan%}
        {%subBrandMenuItems%}
    • {%itemName%} {%arrowSpan%}
        {%productMenuItems%}
    • {%itemKeyName%} {%itemBadges%} {%arrowSpan%}
      {%selfProduct%}
    • {%itemName%}
      • {%countries%}
    • {%allMenuItem%}
      • {%languages%}

      •  

      If the patient’s disease process progresses despite adequate medical treatment, or if there are problems with tolerability or adherence, surgical treatment may be a viable alternative .1-3

       

      • Selective laser trabeculoplasty (SLT)

      • Minimally invasive glaucoma surgery (Micro Incisional Glaucoma filtration Surgery, MIGS)

      • Conventional surgery

       

      What is minimally invasive glaucoma surgery (MIGS)?

      MIGS is a collective name for minimally invasive surgical procedures with improved safety compared with conventional surgery.1–6 MIGS facilitates aqueous outflow through minimal impact on the structures of the eye, while also reducing both surgical and healing times.1 When drops are no longer sufficient to help your patients, minimally invasive glaucoma surgery may be an option.1–3

      Eyedrop containers

      Earlier referral increases treatment benefit

      Although modern, minimally invasive methods are now available, late referrals are still common. It takes an average of 8.5 years (interval 14 days to 40 years) from the time of diagnosis until patient referral for surgery. This is too late for 2/3 of patients; by the time they are referred, IOP has become too high in 22% of patients, while 44.4% have developed advanced functional and structural eye defects.8 If referrals are made earlier, more surgical options are available and patients will experience greater treatment benefit.9–12

      Read more about XEN
      Ganfort

      Ganfort® (bimatoprost+timolol) 0,3 mg/ml+5 mg/ml eye drops, solution, in multidose and single-dose container.

      Indication
      Reduction of intraocular pressure (IOP) in adult patients with open-angle glaucoma or ocular hypertension who are insufficiently responsive to topical beta-blockers or prostaglandin analogues.2

      Lumigan® (bimatoprost) 0,1 mg/ml eye drops, solution, in multidose container and 0,3 mg/ml eye drops, solution, in single-dose container

      Indication
      Reduction of elevated intraocular pressure in chronic open-angle glaucoma and ocular hypertension in adults (as monotherapy or as adjunctive therapy to beta-blockers).1

      References: 1. XXX XXX

      Anmäl dig till vårt nyhetsbrev

      Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in culpa qui officia deserunt mollit.

      Bli prenumerant, klicka här!